Readgene (RDG) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Readgene stock PLN 1.36, price PLN 4.88, upside -72.1%, quality 63 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.
How to read this chart
60‑month range 1.97 PLN – 6.86 PLN · fair‑value band 0.4600 PLN – 1.93 PLN · the 4.88 PLN price screens above the 1.36 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Oct 30, 2026.
Follow Readgene in your weekly email
Every Wednesday you see whether Readgene is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Read-Gene S.A. engages in the detection, prevention, and treating of various types of cancer in Poland. The company offers chemoprevention that uses natural or synthetic substances to inhibit, reverse, or delay the process of developing cancer.
Show moreShow less
It also provides clinical trials that involves evaluating whether a potential drug, product, or medical technology is effective and safe for the medical, pharmaceutical, chemical, and biotechnological industries.
In addition, the company offers genetic tests; and advisory services for genetic counseling and support for oncological genetic counseling centers. Further, it operates an online platform for genetic tests and genetic-oncological consultations.
The company was incorporated in 2005 and is based in Szczecin, Poland. Read-Gene S.A. operates as a subsidiary of Gen-Pat-Med Sp. z o.o.
Stock analysis
Readgene (RDG) currently trades at 4.88 PLN, while our model-based Fair Value estimate is 1.36 PLN, 72.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 2.02 PLN per share, and 0 of the 10 models we run sit above the 4.88 PLN price.
Bear case: the Asset-Based group reads lowest at 0.2100 PLN, and 10 of the 10 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 0.4600 PLN (bear) to 1.93 PLN (bull), the price of 4.88 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Readgene reported revenue of 15.6M PLN in FY2025 versus 6.5M PLN in FY2021, a compound +24.6%/yr. Reported net income was 808K PLN in FY2025, compounding +114.9%/yr from FY2021.
Key figures
Market cap 57.5M PLN (≈ $14.6M) Micro · P/E ratio 48.8 · P/S ratio 2.53 · EPS (TTM) 0.1000 PLN · Net margin 5.2% · Return on equity 16.2% · Return on assets (EBIT) −0.5% · Operating margin −10.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 20% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −72%, RDG screens richer than that median.
Fair Value models
Bear0.4600 PLNFair Value 1.36 PLNBull1.93 PLN
Price 4.88 PLN · Upside -72.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.0833 PLN per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+16.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.9%
Start year 2020 (pandemic). Over 10 years: +21.7% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.7%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+43.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+43.7%
Dividend (yield on the price)0.0%
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−2% → −3%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 588 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score63 · Top 25%
Fair Value upside−72.1% · Bottom 25%
Profitability
Return on equity (12 months)16.2% · Top 25%
Return on assets5.3% · Top 25%
Net margin (12 months)3.1% · Below median
Operating margin (12 months)−10.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)21.6% · Above median
Balance sheet
Debt / equity2.17× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)48.8× · Pricier than median
P/B3.82× · Priciest 25%
P/S (12 months)0.88× · Cheapest 25%
EV/EBITDA13.6× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)65· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Readgene Fair Value". https://www.fairvalue-calculator.com/stock/RDG
Frequently asked questions
Is Readgene (RDG) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of 1.36 PLN versus a price of 4.88 PLN, about −72% upside (overvalued).
What is the fair value of RDG?
Our model-based fair value for Readgene is 1.36 PLN (as of Oct 30, 2026), built from audited fundamentals. The current price: 4.88 PLN.
What is the quality score of RDG?
Readgene has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Readgene (RDG)?
Our model-based price target is the fair value of 1.36 PLN (as of Oct 30, 2026) from 10 valuation models. Cautious scenario 0.4600 PLN, optimistic scenario 1.93 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Readgene stock forecast for 2026?
Our models put fair value at 1.36 PLN, about −72% upside versus a price of 4.88 PLN (overvalued). Cautious scenario 0.4600 PLN, optimistic scenario 1.93 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Readgene (RDG)?
Readgene reported trailing-twelve-month revenue of about 16.7M PLN (latest available figure, as of Oct 30, 2026).
What is the intrinsic value of Readgene (RDG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Readgene it is 1.36 PLN per share (as of Oct 30, 2026), against a price of 4.88 PLN. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Readgene stock overvalued or undervalued in 2026?
As of Oct 30, 2026, RDG trades above its calculated fair value: price 4.88 PLN, fair value 1.36 PLN, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RDG?
No. The price is what the market pays today (4.88 PLN); the fair value is what the company's own numbers justify (1.36 PLN). For Readgene the two are 3.52 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Readgene worth?
The market values Readgene at about 57.5M PLN (market capitalisation, as of Oct 30, 2026). Per share that is 4.88 PLN; our models calculate a fair value of 1.36 PLN per share.
What do the bullish and bearish scenarios say about RDG?
Our models span a range for Readgene: cautious scenario 0.4600 PLN, base 1.36 PLN, optimistic 1.93 PLN per share (as of Oct 30, 2026, price 4.88 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RDG?
Readgene trades at a price-to-earnings ratio of 48.8 (as of Oct 30, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.36 PLN is built from several models across several years. Other multiples: P/B 3.8, P/S 0.9, EV/EBITDA 13.6.
How solid is the balance sheet of Readgene (RDG)?
Balance-sheet figures for Readgene (as of Oct 30, 2026): return on equity 16.2%, debt of 2.17 per unit of equity. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is RDG from its 52-week high?
Readgene trades at 4.88 PLN, about 20% below its 52-week high of 6.08 PLN and 6% above the low of 4.60 PLN (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of 1.36 PLN is for.
Which stocks are comparable to Readgene?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Readgene stock attractive at the current price?
The data as of Oct 30, 2026: price 4.88 PLN, calculated fair value 1.36 PLN (−72%), Quality Score 63/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RDG calculated?
We run Readgene through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.36 PLN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Readgene itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Readgene (RDG)?
The closing price on Oct 30, 2026 was 4.88 PLN. Our model-based fair value is 1.36 PLN, about −72% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Readgene right now?
The price sits above even our optimistic bull case (1.93 PLN). The favourable scenario is already priced in. The model range is unusually wide (0.4600 PLN to 1.93 PLN). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Readgene
How large is the market capitalisation of Readgene (RDG)?
The market capitalisation of Readgene is 57.5M PLN (≈ $14.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Readgene (RDG)?
The price-to-sales ratio of Readgene is 2.53 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Readgene (RDG)?
Earnings per share at Readgene are 0.1000 PLN (price ÷ EPS = P/E 48.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Readgene (RDG)?
The net margin of Readgene is 5.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Readgene (RDG)?
The return on equity (ROE) of Readgene is 16.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Readgene (RDG)?
On an EBIT basis the return on assets of Readgene is −0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Readgene (RDG)?
The operating margin of Readgene is −10.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Readgene (RDG)?
Revenue at Readgene is growing +21.6% versus a year earlier (3y avg +29.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Readgene (RDG) generate?
The free cash flow of Readgene is −128K PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Readgene (RDG) carry?
The net debt of Readgene is 3.1M PLN (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Readgene in the live analysis
One click puts Readgene on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
